Abstract
The colorectal cancer (CRC) prevention in inflammatory bowel disease (IBD) comprises all those measures directed to: long-term control of inflammatory activity in colon, chemo-prevention and the adequate adherence of physicians and patients to endoscopic screening and surveillance (ES) programs recommended by updated consensus clinical practice guidelines (CPG). In the IBD, dysplasia and intra-epithelial neoplasia are the oncogenic precursors of CRC. In the most cases, dysplasia lesions can be discovered by endoscopy. The rroutine use of dye-based pancolonic chromoendoscopy or virtual chomoendoscopty with yargered biopsies/resection is recomended in order to optimize its detection and diagnosis. A good prognosis is related with a complete resection of dysplasia lesions, allowing an endoscopic follow-up according to consensus protocols. Colectomy is indicated either when complete resection (by polypectomy and / or advanced endoscopy techniques) is impossible, or when there are signs of neoplastic invasiveness. Recommendations of the GPC of Asociación Española de Gastroenterología (AEG) and Sociedad Española de Medicina Familiar y Comunitaria (SemFYC) 2018 and Grupo Español de Trabajo en Enfermedad de Crohn y Colitis ulcerosa (GETECCU) 2019, are summarized in the current report.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Medicine - Programa de Formación Médica Continuada acreditado
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
